Online citations, reference lists, and bibliographies.
← Back to Search

The Molecular Basis Of Malignant Pleural Mesothelioma.

Benjamin Wadowski, A. De Rienzo, R. Bueno
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma (MPM) is a rare, aggressive malignancy of the pleural lining associated with asbestos exposure in greater than 80% of cases. It is characterized by molecular heterogeneity both between patients and within individual tumors. Next-generation sequencing technology and novel computational techniques have resulted in a greater understanding of the epigenetic, genetic, and transcriptomic hallmarks of MPM. This article reviews these features and discusses the implications of advances in MPM molecular biology in clinical practice.
This paper references
10.1016/j.jtho.2017.09.1968
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma
N. S. Patil (2018)
10.1016/S1470-2045(17)30169-9
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
E. Alley (2017)
10.1093/jnci/djp061
Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma.
G. Gordon (2009)
10.3322/caac.21572
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
M. Carbone (2019)
10.1016/S0002-9440(10)62492-3
Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.
G. Gordon (2005)
10.5858/arpa.2017-0365-RA
Malignant Mesothelioma and Its Non-Asbestos Causes.
R. Attanoos (2018)
10.3390/ht7030020
Genomics and Epigenetics of Malignant Mesothelioma
Adam P Sage (2018)
10.2217/LMT.15.21
Causes and pathophysiology of malignant pleural mesothelioma
D. Jean (2015)
10.1093/jnci/djy171
Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide
S. Walpole (2018)
10.21037/tlcr.2018.10.04
Malignant peritoneal mesothelioma: a review.
G. Broeckx (2018)
10.1073/pnas.1821510116
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy
R. Hassan (2019)
10.1093/BIOINFORMATICS/BTP659
Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis
R. Shen (2010)
10.1080/14712598.2019.1606209
Immune checkpoint inhibition for the treatment of mesothelioma
A. Nowak (2019)
10.1016/J.LUNGCAN.2007.06.015
DNA methylation profile of 28 potential marker loci in malignant mesothelioma.
Jeffrey A. Tsou (2007)
10.1007/s00280-019-03878-3
The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment
V. Galani (2019)
10.1002/path.1128
Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases
M. Krismann (2002)
10.1158/0008-5472.CAN-15-0751
Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma.
A. De Rienzo (2016)
10.1007/s00204-018-2179-y
DNA methylation profiling of asbestos-treated MeT5A cell line reveals novel pathways implicated in asbestos response
E. Casalone (2018)
10.1016/j.athoracsur.2016.08.063
Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.
W. Vigneswaran (2017)
10.1016/j.jtho.2018.04.023
New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi‐Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center
F. Sallé (2018)
10.1093/bioinformatics/btq182
Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM
Charles J. Vaske (2010)
10.1158/0008-5472.CAN-14-1008
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guangwu Guo (2015)
10.1158/1538-7445.AM2016-112
Abstract 112: Genetic alterations in molecular tumor subgroups of malignant pleural mesothelioma
Lisa Quetel (2016)
10.1016/j.ctrv.2011.01.001
Advances in the biology of malignant pleural mesothelioma.
P. Zucali (2011)
10.1016/j.lungcan.2018.10.015
Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma.
R. Tranchant (2018)
10.1016/j.jmoldx.2016.07.011
Validation of a Gene Expression Test for Mesothelioma Prognosis in Formalin-Fixed Paraffin-Embedded Tissues.
A. De Rienzo (2017)
10.1200/JCO.2018.78.5204
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.
V. Panou (2018)
Gene expression profiling of malignant mesothelioma.
S. Singhal (2003)
10.1002/ajim.22985
Quantitative relationships of exposure to chrysotile asbestos and mesothelioma mortality
D. Loomis (2019)
10.1159/000109618
Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH
P. M. Lindholm (2007)
10.1080/10937404.2011.556051
Role of Mutagenicity in Asbestos Fiber-Induced Carcinogenicity and Other Diseases
Sarah X. L. Huang (2011)
10.1155/2017/1310478
Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
E. Pulford (2017)
10.1093/JNCI/95.8.598
Using gene expression ratios to predict outcome among patients with mesothelioma.
G. Gordon (2003)
10.3389/fonc.2019.01293
Epigenetic Regulation of miRNA Expression in Malignant Mesothelioma: miRNAs as Biomarkers of Early Diagnosis and Therapy
M. Tomasetti (2019)
10.1016/j.semcancer.2019.06.012
Autoimmunity, Checkpoint Inhibitor Therapy and Immune-related Adverse Events: A Review.
Shaheen Khan (2019)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
10.1136/thx.54.7.638
The molecular basis of asbestos induced lung injury
D. Kamp (1999)
10.1378/chest.08-2665
Malignant pleural mesothelioma: an update on biomarkers and treatment.
M. Ray (2009)
10.1038/s41467-019-09307-6
Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications
Y. Blum (2019)
10.1016/j.jtho.2016.05.020
The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing
Marieke Hylebos (2016)
10.1158/1078-0432.CCR-13-2429
Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition
A. de Reyniès (2014)
10.1016/j.jtho.2019.12.111
Brief Report: Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas.
R. Guo (2019)
10.1002/gcc.22381
Different prognostic roles of tumor suppressor gene BAP1 in cancer: A systematic review with meta‐analysis
C. Luchini (2016)
10.1158/0008-5472.CAN-05-3907
Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.
Fernando López-Ríos (2006)
10.1038/nrc3459
BAP1 and cancer
M. Carbone (2013)
10.3390/ijms19061603
Heterogeneity in Malignant Pleural Mesothelioma
K. Oehl (2018)
10.1038/labinvest.3700109
Asbestos-derived reactive oxygen species activate TGF-β1
D. Pociask (2004)
10.1080/15287394.2017.1416911
A genetic variant of NLRP1 gene is associated with asbestos body burden in patients with malignant pleural mesothelioma
S. Crovella (2018)
10.1016/j.freeradbiomed.2017.12.008
Modulation of reactive oxygen species via ERK and STAT3 dependent signalling are involved in the response of mesothelioma cells to exemestane
B. Nuvoli (2018)
10.5858/arpa.2011-0215-RA
Molecular changes in mesothelioma with an impact on prognosis and treatment.
D. Jean (2012)
10.3389/fonc.2020.00105
Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future
G. Reid (2020)
10.1158/0008-5472.CAN-08-2586
Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome.
B. Christensen (2009)
10.1002/path.4567
Epigenetic down‐regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma
V. László (2015)
10.1080/15384047.2016.1145850
Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration
A. Borczuk (2016)
10.1080/15287394.2019.1694612
Pleural mesothelioma and lung cancer: the role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes
F. Celsi (2019)
10.1126/science.aan2507
A pathology atlas of the human cancer transcriptome
M. Uhlén (2017)
10.1158/0008-5472.CAN-09-1595
Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
Y. Goto (2009)
10.1007/s00428-008-0689-3
Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas
S. Dacic (2008)
10.1038/nature22798
BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation
A. Bononi (2017)
10.1158/1078-0432.CCR-04-2181
Validation of Genomics-Based Prognostic Tests in Malignant Pleural Mesothelioma
G. Gordon (2005)
10.1038/nm.3947
Loss of BAP1 function leads to EZH2-dependent transformation
Lindsay M. LaFave (2015)
10.1158/2159-8290.CD-18-0804
Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Julija Hmeljak (2018)
10.1002/jcp.22724
Malignant mesothelioma: Facts, Myths, and Hypotheses
M. Carbone (2012)
10.1016/j.lungcan.2018.07.041
Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.
A. Churg (2018)
10.1038/ng.3520
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
R. Bueno (2016)
Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma.
G. Gordon (2002)
10.1016/J.LUNGCAN.2005.03.018
Transcriptional profiling of mesothelioma using microarrays.
G. Gordon (2005)
10.1158/0008-5472.CAN-10-0190
Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma.
B. Christensen (2010)
10.1158/1078-0432.CCR-0607-3
Gene Expression Profiles Predict Survival and Progression of Pleural Mesothelioma
H. Pass (2004)
10.1016/j.jtho.2018.02.021
Progress in the Management of Malignant Pleural Mesothelioma in 2017
Amanda J McCambridge (2018)
10.1016/j.mrrev.2011.12.003
A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma.
O. Melaiu (2012)
10.1007/978-3-319-53560-9_9
Gene Signature of Malignant Pleural Mesothelioma
A. D. Rienzo (2017)
10.1200/JCO.2018.36.15_SUPPL.8516
The TCGA malignant pleural mesothelioma (MPM) project: VISTA expression and delineation of a novel clinical-molecular subtype of MPM.
M. Ladanyi (2018)
10.1016/j.jtho.2016.06.020
BRCA1‐Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study
L. Righi (2016)
10.1002/cncr.26143
Circulating and tumor‐infiltrating myeloid cells predict survival in human pleural mesothelioma
B. Burt (2011)
10.21037/atm.2017.06.60
Diagnosis and prognosis-review of biomarkers for mesothelioma.
H. H. Sun (2017)
10.1007/978-3-642-10862-4_5
Pathohistological diagnosis and differential diagnosis.
I. Tischoff (2011)
10.1038/nrc.2017.42
Novel insights into mesothelioma biology and implications for therapy
T. Yap (2017)
10.1073/pnas.1309085110
Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair
Helen Yu (2013)
10.1093/annonc/mdu127
Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.
M. Suraokar (2014)
10.1016/j.jtho.2019.03.030
The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.
D. Gomez (2019)
10.1002/gcc.20669
CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma—A miRNA microarray analysis
Mohamed Guled (2009)
10.1016/j.jtho.2017.03.023
A Novel BRCA1‐Associated Protein‐1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1‐Mediated DNA Repair
R. Parrotta (2017)
10.1186/1479-5876-10-179
BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
M. Carbone (2012)
10.1038/modpathol.2015.65
BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations
Marta Cigognetti (2015)
10.1016/S0014-5793(00)01913-X
Differential gene expression in mesothelioma
B. Rihn (2000)
10.1158/1078-0432.CCR-16-1971
Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma
R. Tranchant (2016)
10.18632/oncotarget.13174
Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis
R. Bruno (2017)
10.1007/s00262-016-1844-3
CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor
S. Roncella (2016)
10.1038/ng.855
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew J Bott (2011)



Semantic Scholar Logo Some data provided by SemanticScholar